Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

addiction

- PMLiVE

WHO director-general says pandemic can be brought under control within months

World has tools to curb pandemic if applied ‘consistently and equitably’

- PMLiVE

Unpacking rare diseases in the first edition of Delta magazine

Fishawack Health launches Delta magazine with a deep dive into rare disease commercialization.

Avalere Health

Wearable Technologies for Detecting Pre-Symptomatic Illness and Infections

Dr. Tejaswini Mishra, Research Scientist at Stanford University School of Medicine, dives into her research on using wearable technologies for detecting COVID-19 and other diseases before patients become symptomatic. Among...

Impetus Digital

- PMLiVE

Gilead and Novo Nordisk boost NASH partnership with new mid-stage study

The two companies first announced their NASH collaboration in 2019

- PMLiVE

WHO backs emergency use of J&J’s one-dose COVID-19 vaccine

Vaccine is already approved for emergency use by the European Commission and the FDA

Innovative Approaches to Managing Mental Health Conditions

Owen Muir, MD, CIO at Brooklyn Minds, explores the secondary effects of COVID-19 on mental health conditions, along with techniques such as deep Transcranial Magnetic Stimulation (dTMS), Mentalization-Based Treatment (MBT), and...

Impetus Digital

- PMLiVE

J&J submits one-dose COVID-19 vaccine to WHO for emergency use listing

In phase 3, J&J's vaccine was 66% effective overall at preventing moderate-to-severe COVID-19

- PMLiVE

WHO agrees to no-fault compensation for rare serious side effects from COVAX-distributed vaccines

The no-fault compensation fund will be accessible via a web portal by 31 March 2021

Risk Management, Ethics, and Compliance Considerations in the New Normal

Myriam Prescott, Head of Ethics, Risks and Compliance - Oncology, Novartis Canada, dissects the importance of effective patient engagement and strong compliance & monitoring programs. We also dive into the...

Impetus Digital

- PMLiVE

WHO grants emergency use listing for AZ/Oxford University’s COVID-19 vaccine

The emergency use listing authorises the use of the vaccine in all adults, including over-65s

- PMLiVE

WHO backs AZ/Oxford COVID-19 vaccine, including in older adults

WHO's Sage panel also recommends a two-dose regimen given eight to 12 weeks apart

- PMLiVE

Pfizer/BioNTech reach vaccine supply agreement with COVAX

Up to 40 million doses will be supplied to the international vaccine-sharing facility

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links